Table 8.

Prevalence (%) of Variants Based on the BZLF-1 Promoter (Zp) by Clinical Condition and Geographic Region

Health condition	Zp	China	Africa	N./ S. America	Europe
NPC	Zp-P	13.0%
	Zp-V3	82.6%
	Zp-V4	0.0%
	Zp-PV	0.0%
	Multiple/Other	4.3%
	Total	46	0	0	0
NHL	Zp-P	100%	71.4%	45.8%
	Zp-V3	0.0%	28.6%	54.2%
	Zp-V4	0.0%	0.0%	0.0%
	Zp-PV	0.0%	0.0%	0.0%
	Multiple/Other	0.0%	0.0%	0.0%
	Total	3	7	24	0
AIDS lymphoma	Zp-P				54.0%
	Zp-V3				30.2%
	Zp-V4				0.0%
	Zp-PV				11.1%
	Multiple/Other				4.8%
	Total	0	0	0	63
Non-malignant/healthy	Zp-P	47.5%		81.3%	70.0%
	Zp-V3	50.0%		0.0%	0.0%
	Zp-V4	0.0%		18.8%	0.0%
	Zp-PV	0.0%		0.0%	0.0%
	Multiple/Other	2.5%		0.0%	30.0%a
	Total	40	0	16	20

(Gutierrez et al., 2002; Martini et al., 2007; Tong et al., 2003)

^aZp-P + Zp-V3